Table 2.

Study endpoints by baseline diabetes status

Endpoint	Aliskiren, n (%) Non-DM (n = 489) DM (n = 319)	Placebo, n (%) Non-DM (n = 464) DM (n = 343)	Hazard ratio (95% CI)	P for interaction (two-sided)
Primary endpoint (6 months)
CV death or HF rehospitalization
Non-DM	102 (20.9)	114 (24.6)	0.80 (0.61–1.04)
DM	99 (31.0)	100 (29.2)	1.13 (0.86–1.50)	0.08
Secondary endpoints (12 months, unless otherwise specified)
CV death or HF rehospitalization
Non-DM	148 (30.3)	165 (35.6)	0.80 (0.64–0.99)
DM	135 (42.3)	136 (39.7)	1.16 (0.91–1.47)	0.03
First CV event
Non-DM	154 (31.5)	177 (38.1)	0.75 (0.61–0.94)
DM	139 (43.6)	144 (42.0)	1.11 (0.88–1.40)	0.02
All-cause death (6 months)
Non-DM	43 (8.8)	51 (11.0)	0.75 (0.50–1.13)
DM	42 (13.2)	38 (11.1)	1.38 (0.88–2.15)	0.05
All-cause death
Non-DM	72 (14.7)	91 (19.6)	0.69 (0.50–0.94)
DM	72 (22.6)	57 (16.6)	1.64 (1.15–2.33)	<0.01

CI, confidence interval; CV, cardiovascular; DM, diabetes mellitus; HF, heart failure.